Forest Takes On Merck, Novartis In Hypertension; Benicar Another Lexapro?
Executive Summary
Forest/Sankyo's Benicar is rivaling Novartis' Diovan in the number of new patient starts in the angiotensin II inhibitor antihypertensive class, Forest President Kenneth Goodman told the Friedman Billings Ramsey growth conference June 2 in New York